Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Common Equity (2020 - 2025)

Sight Sciences (SGHT) has 6 years of Common Equity data on record, last reported at $63.9 million in Q4 2025.

  • For Q4 2025, Common Equity fell 26.94% year-over-year to $63.9 million; the TTM value through Dec 2025 reached $63.9 million, down 26.94%, while the annual FY2025 figure was $63.9 million, 26.94% down from the prior year.
  • Common Equity reached $63.9 million in Q4 2025 per SGHT's latest filing, down from $64.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $232.1 million in Q4 2021 and bottomed at -$246.0 million in Q3 2021.
  • Average Common Equity over 5 years is $85.2 million, with a median of $105.4 million recorded in 2024.
  • The widest YoY moves for Common Equity: up 361.24% in 2021, down 207.62% in 2021.
  • A 5-year view of Common Equity shows it stood at $232.1 million in 2021, then crashed by 31.03% to $160.1 million in 2022, then decreased by 24.9% to $120.2 million in 2023, then decreased by 27.19% to $87.5 million in 2024, then dropped by 26.94% to $63.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $63.9 million in Q4 2025, $64.3 million in Q3 2025, and $70.0 million in Q2 2025.